期刊
WORLD JOURNAL OF HEPATOLOGY
卷 6, 期 5, 页码 326-339出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4254/wjh.v6.i5.326
关键词
Protease inhibitor; PEGylated interferon-alpha; Ribavirin; Antiviral treatment; Adverse event; Response-guided therapy; Hepatitis C virus
A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-a and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings. (c) 2014 Baishideng Publishing Group Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据